On September 22, 2022, Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG, and existing investors Longitude Capital, Medicxi, and RxCapital. Wilson Sonsini Goodrich & Rosati advised RA Capital in the transaction.

Funds from the Series B will primarily be used to further support clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease.

The Wilson Sonsini team that advised RA Capital on the transaction includes:

Corporate 
Jennifer Fang
Amanda Creedon
Elke Trilla

Patents and Innovations
Mike Hostetler
Deborah Smith
Celine Bonnefous

Regulatory
Eva Yin

Technology Transactions
Morgan Brown

For more information, please see Rivus Pharmaceuticals' news release.